Skip to main content

Table 1 Baseline characteristics and demographics of subjects in the SUSTAIN 6 trial

From: Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

A. Post hoc analysis by gender
  Semaglutide Placebo
Male Female Male Female
 Subject demographics
  Full analysis set, N 1013 635 989 660
  Trial completers, n (%) 959 (94.7) 602 (94.8) 926 (93.6) 623 (94.4)
  Treatment completers, n (%) 773 (76.3) 481 (75.7) 788 (79.7) 514 (77.9)
 Baseline characteristicsa
  Age, years 64.6 (7.3) 64.8 (7.1) 64.6 (7.6) 64.6 (7.5)
  Body weight, kg 96.7 (20.5) 85.4 (19.0) 95.8 (21.0) 86.0 (18.4)
  BMI, kg/m2 32.3 (5.9) 33.7 (6.6) 32.1 (6.0) 33.9 (6.3)
  Diabetes duration, years 13.9 (8.1) 14.5 (8.4) 13.5 (8.0) 13.8 (8.1)
  HbA1c, % 8.6 (1.4) 8.8 (1.6) 8.6 (1.4) 8.8 (1.6)
  Smoking status (never/previous/current), % 33.5/51.7/14.8 65.4/26.1/8.5 30.1/56.1/13.7 66.8/23.0/10.2
B. Post hoc analysis by age
  Semaglutide Placebo
≤ 65 years > 65 years ≤ 65 years > 65 years
 Subject demographics
  Full analysis set, N 950 698 929 720
  Trial completers, n (%) 899 (94.6) 662 (94.8) 875 (94.2) 674 (93.6)
  Treatment completers, n (%) 745 (78.4) 509 (72.9) 745 (80.2) 557 (77.4)
 Baseline characteristicsb
  Age, years 59.7 (4.1) 71.4 (4.7) 59.2 (4.3) 71.6 (4.5)
  Females, % 38.4 38.7 40.9 38.9
  Body weight, kg 94.0 (21.1) 90.0 (19.8) 93.0 (21.4) 90.5 (19.3)
  BMI, kg/m2 33.3 (6.4) 32.2 (5.9) 33.1 (6.4) 32.4 (5.8)
  Diabetes duration, years 12.6 (7.2) 16.4 (8.9) 12.4 (7.4) 15.2 (8.5)
  HbA1c, % 8.9 (1.6) 8.4 (1.2) 8.9 (1.6) 8.4 (1.3)
  Smoking status (never/previous/current),  % 47.0/37.1/16.0 44.1/48.4/7.5 45.3/39.0/15.7 44.2/47.9/7.8
C. Post hoc analyses by CV risk profile at baseline
  Semaglutide Placebo Semaglutide Placebo
Prior MI/stroke No prior MI/stroke Prior MI/stroke No prior MI/stroke Established CVD CV risk factors Established CVD CV risk factors
 Full analysis set, N 673 975 694 955 1262 386 1271 378
 Baseline characteristics
  Age, years 63.8 (7.5) 65.2 (6.9) 63.6 (7.9) 65.3 (7.2) 64.2 (7.3) 66.1 (6.5) 64.2 (7.7) 66.0 (6.7)
  Female, n (%) 208 (30.9) 427 (43.8) 225 (32.4) 435 (45.5) 445 (35.3) 190 (49.2) 463 (36.4) 197 (52.1)
  Diabetes duration, years 13.7 (8.5) 14.5 (8.0) 13.3 (8.1) 13.8 (8.0) 14.0 (8.4) 14.8 (7.6) 13.3 (7.9) 14.6 (8.2)
  BMI, kg/m2 32.6 (6.0) 33.0 (6.4) 32.7 (6.2) 32.8 (6.2) 32.8 (6.1) 32.8 (6.5) 33.0 (6.2) 32.3 (6.1)
  HbA1c, % 8.8 (1.6) 8.7 (1.4) 8.7 (1.5) 8.7 (1.4) 8.7 (1.5) 8.7 (1.4) 8.7 (1.5) 8.7 (1.5)
 CV risk factors
  Systolic blood pressure, mmHg 134.6 (17.7) 136.9 (17.3) 134.9 (17.1) 135.5 (16.6) 135.5 (17.5) 137.5 (17.5) 134.9 (16.6) 136.5 (17.4)
  Diastolic blood pressure, mmHg 76.8 (9.9) 77.1 (10.1) 76.7 (10.4) 77.4 (9.8) 76.7 (10.0) 77.9 (9.8) 77.0 (10.2) 77.5 (9.6)
  Total cholesterol, mmol/L [mean (CoV)] 4.2 (26.8) 4.4 (25.5) 4.2 (27.9) 4.3 (26.5) 4.3 (26.9) 4.4 (23.6) 4.2 (27.6) 4.4 (25.4)
  eGFR, mL/min/1.73 m2 [mean (CoV)] 72.1 (39.2) 70.1 (41.4) 73.8 (39.8) 69.0 (44.6) 72.9 (38.7) 64.9 (44.8) 73.9 (39.7) 61.7 (49.2)
  Current smoker, n (%) 106 (15.8) 98 (10.1) 109 (15.7) 93 (9.74) 170 (13.5) 34 (8.8) 167 (13.1) 35 (9.3)
 Manifestation of CVD
  Prior MI, n (%) 530 (78.8) 542 (78.1) 530 (42.0) 542 (42.6)
  Ischemic heart disease, n (%) 571 (84.8) 417 (42.8) 589 (84.9) 417 (43.7) 988 (78.3) 1006 (79.2)
  Prior stroke, n (%) 191 (28.4) 210 (30.3) 191 (15.1) 210 (16.5)
  Peripheral arterial disease, n (%) 87 (12.9) 139 (14.3) 89 (12.8) 138 (14.5) 226 (17.9) 227 (17.9)
  ≥ 50% arterial stenosis, n (%) 327 (48.6) 240 (24.6) 361 (52.0) 239 (25.0) 567 (44.9) 600 (47.2)
  Percutaneous coronary intervention, n (%) 327 (48.6) 163 (16.7) 342 (49.3) 180 (18.8) 490 (38.8) 522 (41.1)
  Coronary artery bypass graft, n (%) 182 (27.0) 106 (10.9) 182 (26.2) 107 (11.2) 288 (22.8) 289 (227)
  Heart failure, n (%) 187 (27.8) 194 (19.9) 185 (26.7) 211 (22.1) 381 (30.2) 396 (31.2)
  1. Data presented as mean (SD) unless otherwise indicated. Data were pooled for semaglutide groups and placebo groups in each SUSTAIN 6 subgroup
  2. BMI body mass index, CoV coefficient of variation, CV cardiovascular, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, MI myocardial infarction, SD standard deviation
  3. aNumbers are based on an in-trial analysis comprising events with onset on or after the day of randomization and until end of trial
  4. bData were pooled for semaglutide groups and placebo groups in each SUSTAIN 6 subgroup